Call for papers accelerates cancer information transfer - ecancermedicalscience

ecancermedicalscience aims to improve communications between sub-specialised cancer scientists and clinicians by working interactively and faster - offering authors a rapid peer review process. Submit your paper and you'll hear if it will be published within three weeks.

ecancermedicalscience (ISSN 1754-6605) is an independent online journal, publishing research articles after full peer review. All articles are published online immediately upon acceptance. The journal is published by Cancer Intelligence Ltd, Westpoint, 78 Queens Road, Clifton, Bristol, BS8 1QU.

ecancermedicalscience, founded by the European Institute of oncology, is proud to acknowledge The European CanCer Organisation as its educational and Scientific partner.

Criteria for publication
Publication of research articles by ecancermedicalscience is dependent primarily on their validity and coherence, as judged by a peer reviewer. The reviewer is asked how remarkable they consider the article to be. ecancermedicalscience is interested in publishing; innovative studies testing new hypotheses; policy research papers that challenge conventional thinking and case studies that address new and interesting ways of working.

Speed of publication
ecancermedicalscience offers fast publication whilst maintaining rigorous peer review; all articles must be submitted online, and peer review is managed electronically. A web version, and accompanying PDF, will be published within a few days of acceptance.

For further information, please visit:
http://www.ecancermedicalscience.com

Most Popular Now

Therapy using dual immune system cells effectively…

A newly developed immunotherapy that simultaneously uses modified immune-fighting cells to home in on and attack two antigens, or foreign substances, on cancer cells was ...

Cleveland Clinic study suggests steroid nasal spra…

A recent Cleveland Clinic study found that patients who regularly use steroid nasal sprays are less likely to develop severe COVID-19-related disease, including a 20 to 2...

How to develop new drugs based on merged datasets

Polymorphs are molecules that have different molecular packing arrangements despite identical chemical compositions. In a recent paper, researchers at GlaxoSmithKline (GS...

New drug combination effective against SARS-CoV-2 …

More countries with greater resources are opening up for a more normal life. But COVID-19 and the SARS-CoV-2 virus are still a significant threat in large parts of the wo...

Sanofi to focus its COVID-19 development efforts o…

Recent positive interim results of Sanofi's mRNA-based COVID-19 vaccine candidate Phase 1/2 study confirm the company's platform robust capabilities and strategy in mRNA...

Discovery of mechanics of drug targets for COVID-1…

A team of international researchers, including McGill Professor Stéphane Laporte, have discovered the working mechanism of potential drug targets for various diseases suc...

Phase II/III trial shows Ronapreve™ (casirivimab a…

Roche (SIX: RO, ROG; OTCQX: RHHBY) today confirmed positive data from the phase II/III 2066 study, investigating Ronapreve™ (casirivimab and imdevimab) in patients hospit...

Pfizer and BioNTech receive first U.S. FDA Emergen…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced that the U.S. Food and Drug Administration (FDA) has authorized for emergency use a booster dose of the P...

AZD7442 request for Emergency Use Authorization fo…

AstraZeneca has submitted a request to the US Food and Drug Administration (FDA) for an Emergency Use Authorization (EUA) for AZD7442, its long-acting antibody (LAAB) com...

Pfizer and BioNTech receive CHMP positive opinion …

Pfizer Inc. (NYSE: PFE, "Pfizer") and BioNTech SE (Nasdaq: BNTX, "BioNTech") today announced that the Committee for Medicinal Products for Human Use (CHMP) of the Europea...

Boehringer Ingelheim acquires Abexxa Biologics to …

Boehringer Ingelheim announced the acquisition of Abexxa Biologics Inc., a biopharmaceutical company taking a new approach in the fields of immuno-oncology and oncology r...

GSK welcomes WHO recommendation for broad roll-out…

GlaxoSmithKline (GSK) plc welcomes and applauds the WHO recommendation for the broader deployment of GSK's RTS,S malaria vaccine to reduce childhood illness and deaths fr...